At the time we designed our study, anti–PD-1 and PD-L1 antibodies were being evaluated in the second-line setting for NSCLC with significantly improved survival and tolerability compared to docetaxel (7–10). This evidence concerns the gene CD274 and non-small cell lung carcinoma.